Printer Friendly

ATL REPORTS PRELIMINARY SECOND QUARTER RESULTS

 BOTHELL, Wash., July 13 /PRNewswire/ -- ATL (Advanced Technology Laboratories, Inc.) (NASDAQ-NMS: ATLI) said today that second quarter revenues were approximately $75 million and below management expectations. As previously reported in a company press release, ATL said the uncertain impact of U.S. health care reform legislation is adversely affecting domestic revenues. U.S. hospitals and clinics deferred medical equipment expenditures during the quarter to a greater degree than previously anticipated increasing competitive pressures for domestic sales. Business in the United States accounts for slightly over half of the company's revenues. The growth of ATL's international revenues continued through the second quarter of 1993.
 The domestic revenue shortfall in the second quarter, together with planned, higher operating expenses associated with research and development programs and the introduction of Extended Signal Processing, a major advance of ATL's Ultramark(R) 9 High Definition(TM) Imaging system, will result in a loss of between $1.5 million and $2.0 million for the second quarter, or 14 cents to 18 cents per share. For the second quarter of 1992, ATL reported a net loss of $2.1 million, or 19 cents per share, which included two nonrecurring charges totaling $5.0 million directly related to the distribution of the stock of SpaceLabs Medical (NASDAQ-NMS: SLMD) to the shareholders of Westmark International.
 "We will continue to invest in our product development programs as planned. However, in light of the current U.S. market conditions, we are accelerating a number of corporate cost-cutting measures already underway," said Dennis C. Fill, chairman and chief executive officer.
 In February 1993, the ATL Board of Directors authorized the company to buy back up to one million shares of company stock. As of the close of the second quarter, the company had repurchased a total of 469,000 shares of company stock, bringing total shares outstanding to 10.8 million.
 ATL, with headquarters in Bothell, is a worldwide leader in the development, manufacture, marketing and service of medical ultrasound systems.
 -0- 7/13/93
 /CONTACT: Anne Marie Bugge of Advanced Technology Laboratories, 206-487-7081/
 (ATLI SLMD)


CO: Advanced Technology Laboratories; SpaceLabs Medical ST: Washington IN: MTC SU:

SB -- SE009 -- 1029 07/13/93 16:23 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 13, 1993
Words:365
Previous Article:SPECIALTY PAPERBOARD ANNOUNCES PURPORTED CLASS ACTION COMPLAINT
Next Article:EMERGENCY MEDICAL CARE FOR KIDS: WHAT CAN PARENTS DO?
Topics:


Related Articles
WESTMARK REPORTS RECORD EARNINGS, RECOMMENDS DISTRIBUTION OF SPACELABS SHARES AS STOCK DIVIDEND
WESTMARK'S FINAL QUARTER REPORTED; EARNINGS 64 CENTS PER SHARE BEFORE SPIN-OFF CHARGES
ATL REPORTS RECORD REVENUES
ATL REPORTS SECOND QUARTER FINANCIAL RESULTS
ATL REPORTS THIRD QUARTER FINANCIAL RESULTS
ATL REPORTS 1993 RESULTS AND ANNOUNCES PLANS TO ACQUIRE INTERSPEC INC.
ATL ESTIMATES PRELIMINARY THIRD QUARTER REVENUES
ATL REPORTS HIGHER SECOND QUARTER REVENUES AND PROFITABILITY
ATL NET INCOME TRIPLES IN SECOND QUARTER BEFORE NON-RECURRING LEGAL CHARGE
ATL Announces Record Financial Results and New Breakthrough Product

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters